Accueil>>Signaling Pathways>> GPCR/G protein>> Adenosine Receptor>>N-[(4-Aminophenyl)methyl]adenosine

N-[(4-Aminophenyl)methyl]adenosine

Catalog No.GC36676

La N-[(4-aminophényl)méthyl]adénosine est un inhibiteur du récepteur de l'adénosine, avec un Ki de 29 nM pour l'ecto-5′-nucléotidase de rat.

Products are for research use only. Not for human use. We do not sell to patients.

N-[(4-Aminophenyl)methyl]adenosine Chemical Structure

Cas No.: 95523-13-0

Taille Prix Stock Qté
5 mg
225,00 $US
En stock
10 mg
338,00 $US
En stock
50 mg
1 013,00 $US
En stock
100 mg
1 768,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

N-[(4-Aminophenyl)methyl]adenosine is a adenosine receptor inhibitor, with Ki of 29 nM for Rat ecto-5′-Nucleotidase.IC50 value: 29.0 ± 1.7 nM (Ki) Target: Adenosine Receptor

[1]. Bhattarai S, et al. α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5'-Nucleotidase (CD73) Inhibitors. J Med Chem. 2015 Aug 13;58(15):6248-63. [2]. Chen JB, et al. Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection. ChemMedChem. 2011 Aug 1;6(8):1390-400. [3]. Zhu Z, et al. Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity. Bioorg Med Chem. 2008 Apr 1;16(7):3848-65.

Avis

Review for N-[(4-Aminophenyl)methyl]adenosine

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for N-[(4-Aminophenyl)methyl]adenosine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.